<p>Ardelyx, Inc.（納斯達克代碼：ARDX - 獲取免費報告）首席執行官 Michael Raab 於 3 月 16 日（星期一）出售了 41,666 股公司股票。股票的平均售價為 5.84 美元，總價值為 243,329.44 美元。交易完成後，首席執行官直接持有公司 1,816,448 股，價值為 10,608,056.32 美元。這代表其持股比例減少了 2.24%。此次出售在提交給證券交易委員會的文件中披露，您可以通過此鏈接訪問該文件。</p>
<ul>
<li>華爾街喜愛的 3 只市值低於 20 美元的中型股</li>
</ul>
<p>Michael Raab 最近還進行了以下交易：</p>
<ul>
<li>在 2 月 20 日（星期五），Michael Raab 出售了 45,982 股 Ardelyx 股票。股票的平均售價為 5.85 美元，總價值為 268,994.70 美元。</li>
</ul>
<h2>Ardelyx 股價下跌 4.8%</h2>
<p>在週三的午盤交易中，ARDX 股票下跌 0.28 美元，達到 5.55 美元。該公司的股票交易量為 2,907,115 股，而其平均交易量為 4,895,942 股。Ardelyx, Inc.的 12 個月最低價為 3.21 美元，最高價為 8.40 美元。該公司的流動比率為 4.31，速動比率為 4.11，債務與股本比率為 1.21。該公司的 50 日移動平均價格為 6.88 美元，200 日移動平均價格為 6.16 美元。該公司的市值為 13.6 億美元，市盈率為-22.20，貝塔值為 0.61。</p>
<ul>
<li>Ardelyx 在 2022 年初下滑後是否值得購買</li>
</ul>
<p>Ardelyx（納斯達克代碼：ARDX - 獲取免費報告）最近在 2 月 19 日（星期四）發佈了季度財報。這家生物製藥公司報告本季度每股收益（EPS）為-0.01 美元，低於分析師一致預期的 0.02 美元，差距為 0.03 美元。該公司的季度收入為 1.2522 億美元，而一致預期為 1.1804 億美元。Ardelyx 的股本回報率為-40.63%，淨利潤率為-15.12%。Ardelyx 的季度收入同比增長 7.8%。在去年同期，該公司每股收益為 0.02 美元。根據分析師的預測，Ardelyx, Inc.在當前年度的每股收益將為-0.18 美元。</p>
<h2>分析師評級升級與降級</h2>
<p>幾位研究分析師最近對該股票發佈了報告。Raymond James Financial 在 1 月 8 日（星期四）的研究報告中重申了對 Ardelyx 的 “強力買入” 評級，並設定了 19.00 美元的目標價。Leerink Partners 在 3 月 12 日（星期四）的研究報告中重申了對 Ardelyx 的 “跑贏大盤” 評級。Weiss Ratings 在 1 月 21 日（星期三）的報告中重申了對 Ardelyx 的 “賣出（d-）” 評級。Williams Trading 在 3 月 12 日（星期四）的研究報告中設定了 17.00 美元的目標價。最後，花旗集團在 1 月 9 日（星期五）的研究報告中將 Ardelyx 的目標價從 11.00 美元上調至 14.00 美元，並給予該公司 “買入” 評級。一位研究分析師對該股票給予了強力買入評級，八位分析師給予了買入評級，一位分析師對該公司的股票給予了賣出評級。根據 MarketBeat.com 的數據，該股票目前的平均評級為 “適度買入”，共識目標價為 15.70 美元。</p>
<p><strong>獲取我們對 ARDX 的最新股票分析</strong></p>
<h2>機構資金流入與流出</h2>
<p>一些對沖基金最近對 ARDX 的持倉進行了調整。DCF Advisers LLC 在第二季度收購了 Ardelyx 的新股份，價值約 39,000 美元。First Horizon Corp 在第四季度將其在 Ardelyx 的持股增加了 120.4%。First Horizon Corp 目前持有 7,906 股生物製藥公司的股票，價值 46,000 美元，此前在上個季度購買了 4,319 股。SBI Securities Co. Ltd.在第三季度將其在 Ardelyx 的持股增加了 147.0%。SBI Securities Co. Ltd.目前持有 10,253 股生物製藥公司的股票，價值 56,000 美元，此前在上個季度購買了 6,102 股。瑞士人壽資產管理有限公司在第三季度收購了 Ardelyx 的新股份，價值約 57,000 美元。最後，住友三井信託集團在第四季度收購了 Ardelyx 的新股份，價值約 60,000 美元。目前 58.92% 的股票由機構投資者和對沖基金持有。</p>
<h2>Ardelyx 公司簡介</h2>
<p>（獲取免費報告）</p>
<p>Ardelyx, Inc.（納斯達克：ARDX）是一家臨牀階段的生物製藥公司，專注於發現、開發和商業化針對心腎和胃腸疾病的小分子靶向藥物。該公司的主要市場產品 tenapanor（在美國以品牌名 XPHOZAH 銷售）已獲批准用於治療接受透析的慢性腎病患者的高磷血癥。Ardelyx 的專有方法針對胃腸道中的上皮轉運蛋白，提供局部作用並限制全身暴露。</p>
<p>除了 tenapanor，Ardelyx 的開發管道還包括旨在解決腎病及相關代謝紊亂的其他併發症的治療方案。</p>
<h2>特色文章</h2>
<ul>
<li>五隻我們更看好的股票，勝過 Ardelyx</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QVJEWA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QVJEWA"/></p>
<p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1,000 美元在 Ardelyx 嗎？</h2>
<p>在你考慮 Ardelyx 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，以便在更廣泛的市場注意到之前購買……而 Ardelyx 並不在名單上。</p>
<p>雖然 Ardelyx 目前在分析師中被評為適度買入，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

紐交所高增長板生物技術指數 ETF - First Trust

標普生物技術 ETF - SPDR

2 倍做多納斯達克生物技術 ETF - ProShares

ARDX

醫藥突破 ETF - ALPS

生物科技 ETF - VanEck Vectors

標普生物技術 3 倍做多 - Direxion

動態生物技術與基因組 ETF - Invesco

納斯達克生物科技指數 ETF - iShares Nasdaq

基因改革 ETF - ARK

<p>Ardelyx, Inc. 首席執行官 Michael Raab 出售了 41,666 股股票，平均價格為 5.84 美元，總計 243,329.44 美元，導致其持股比例減少 2.24%。出售後，他持有 1,816,448 股，價值約 1060 萬美元。該股票最近下跌 4.8%，報 5.55 美元，市值為 13.6 億美元。分析師對該股票的評級不一，普遍目標價為 15.70 美元。機構投資者最近也對 Ardelyx 股票的持倉進行了調整</p>

<p>Ardelyx, Inc. (NASDAQ:ARDX - Get Free Report) CEO Michael Raab sold 41,666 shares of the business's stock in a transaction dated Monday, March 16th. The shares were sold at an average price of $5.84, for a total value of $243,329.44. Following the completion of the transaction, the chief executive officer directly owned 1,816,448 shares in the company, valued at $10,608,056.32. This represents a 2.24% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities &amp; Exchange Commission, which can be accessed through this hyperlink.</p>
<div class="lb-trans"><p>Ardelyx, Inc.（納斯達克代碼：ARDX - 獲取免費報告）首席執行官 Michael Raab 於 3 月 16 日（星期一）出售了 41,666 股公司股票。股票的平均售價為 5.84 美元，總價值為 243,329.44 美元。交易完成後，首席執行官直接持有公司 1,816,448 股，價值為 10,608,056.32 美元。這代表其持股比例減少了 2.24%。此次出售在提交給證券交易委員會的文件中披露，您可以通過此鏈接訪問該文件。</p>
</div><ul>
<li>3 mid-caps under $20 that Wall Street loves</li>
</ul>
<div class="lb-trans"><ul>
<li>華爾街喜愛的 3 只市值低於 20 美元的中型股</li>
</ul>
</div><p>Michael Raab also recently made the following trade(s):</p>
<div class="lb-trans"><p>Michael Raab 最近還進行了以下交易：</p>
</div><ul>
<li>On Friday, February 20th, Michael Raab sold 45,982 shares of Ardelyx stock. The stock was sold at an average price of $5.85, for a total value of $268,994.70.</li>
</ul>
<div class="lb-trans"><ul>
<li>在 2 月 20 日（星期五），Michael Raab 出售了 45,982 股 Ardelyx 股票。股票的平均售價為 5.85 美元，總價值為 268,994.70 美元。</li>
</ul>
</div><h2>Ardelyx Trading Down 4.8%</h2>
<div class="lb-trans"><h2>Ardelyx 股價下跌 4.8%</h2>
</div><p>ARDX stock traded down $0.28 during mid-day trading on Wednesday, reaching $5.55. The company's stock had a trading volume of 2,907,115 shares, compared to its average volume of 4,895,942. Ardelyx, Inc. has a 12 month low of $3.21 and a 12 month high of $8.40. The company has a current ratio of 4.31, a quick ratio of 4.11 and a debt-to-equity ratio of 1.21. The business's 50 day moving average price is $6.88 and its 200 day moving average price is $6.16. The company has a market cap of $1.36 billion, a price-to-earnings ratio of -22.20 and a beta of 0.61.</p>
<div class="lb-trans"><p>在週三的午盤交易中，ARDX 股票下跌 0.28 美元，達到 5.55 美元。該公司的股票交易量為 2,907,115 股，而其平均交易量為 4,895,942 股。Ardelyx, Inc.的 12 個月最低價為 3.21 美元，最高價為 8.40 美元。該公司的流動比率為 4.31，速動比率為 4.11，債務與股本比率為 1.21。該公司的 50 日移動平均價格為 6.88 美元，200 日移動平均價格為 6.16 美元。該公司的市值為 13.6 億美元，市盈率為-22.20，貝塔值為 0.61。</p>
</div><ul>
<li>Is Ardelyx is A Buy After Slip in Early 2022</li>
</ul>
<div class="lb-trans"><ul>
<li>Ardelyx 在 2022 年初下滑後是否值得購買</li>
</ul>
</div><p>Ardelyx (NASDAQ:ARDX - Get Free Report) last posted its quarterly earnings results on Thursday, February 19th. The biopharmaceutical company reported ($0.01) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.02 by ($0.03). The business had revenue of $125.22 million for the quarter, compared to the consensus estimate of $118.04 million. Ardelyx had a negative return on equity of 40.63% and a negative net margin of 15.12%.Ardelyx's quarterly revenue was up 7.8% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.02 earnings per share. On average, equities research analysts predict that Ardelyx, Inc. will post -0.18 EPS for the current year.</p>
<div class="lb-trans"><p>Ardelyx（納斯達克代碼：ARDX - 獲取免費報告）最近在 2 月 19 日（星期四）發佈了季度財報。這家生物製藥公司報告本季度每股收益（EPS）為-0.01 美元，低於分析師一致預期的 0.02 美元，差距為 0.03 美元。該公司的季度收入為 1.2522 億美元，而一致預期為 1.1804 億美元。Ardelyx 的股本回報率為-40.63%，淨利潤率為-15.12%。Ardelyx 的季度收入同比增長 7.8%。在去年同期，該公司每股收益為 0.02 美元。根據分析師的預測，Ardelyx, Inc.在當前年度的每股收益將為-0.18 美元。</p>
</div><h2>Analyst Upgrades and Downgrades</h2>
<div class="lb-trans"><h2>分析師評級升級與降級</h2>
</div><p>Several research analysts recently issued reports on the stock. Raymond James Financial reissued a &#34;strong-buy&#34; rating and set a $19.00 target price on shares of Ardelyx in a research note on Thursday, January 8th. Leerink Partners reaffirmed an &#34;outperform&#34; rating on shares of Ardelyx in a research note on Thursday, March 12th. Weiss Ratings reiterated a &#34;sell (d-)&#34; rating on shares of Ardelyx in a report on Wednesday, January 21st. Williams Trading set a $17.00 price objective on shares of Ardelyx in a research report on Thursday, March 12th. Finally, Citigroup raised their target price on Ardelyx from $11.00 to $14.00 and gave the company a &#34;buy&#34; rating in a research note on Friday, January 9th. One research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and one has issued a Sell rating to the company's stock. According to MarketBeat.com, the stock currently has an average rating of &#34;Moderate Buy&#34; and a consensus price target of $15.70.</p>
<div class="lb-trans"><p>幾位研究分析師最近對該股票發佈了報告。Raymond James Financial 在 1 月 8 日（星期四）的研究報告中重申了對 Ardelyx 的 “強力買入” 評級，並設定了 19.00 美元的目標價。Leerink Partners 在 3 月 12 日（星期四）的研究報告中重申了對 Ardelyx 的 “跑贏大盤” 評級。Weiss Ratings 在 1 月 21 日（星期三）的報告中重申了對 Ardelyx 的 “賣出（d-）” 評級。Williams Trading 在 3 月 12 日（星期四）的研究報告中設定了 17.00 美元的目標價。最後，花旗集團在 1 月 9 日（星期五）的研究報告中將 Ardelyx 的目標價從 11.00 美元上調至 14.00 美元，並給予該公司 “買入” 評級。一位研究分析師對該股票給予了強力買入評級，八位分析師給予了買入評級，一位分析師對該公司的股票給予了賣出評級。根據 MarketBeat.com 的數據，該股票目前的平均評級為 “適度買入”，共識目標價為 15.70 美元。</p>
</div><p><strong>Get Our Latest Stock Analysis on ARDX</strong></p>
<div class="lb-trans"><p><strong>獲取我們對 ARDX 的最新股票分析</strong></p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>機構資金流入與流出</h2>
</div><p>A number of hedge funds have recently made changes to their positions in ARDX. DCF Advisers LLC acquired a new stake in shares of Ardelyx in the 2nd quarter worth about $39,000. First Horizon Corp boosted its stake in Ardelyx by 120.4% during the 4th quarter. First Horizon Corp now owns 7,906 shares of the biopharmaceutical company's stock valued at $46,000 after purchasing an additional 4,319 shares during the last quarter. SBI Securities Co. Ltd. increased its holdings in Ardelyx by 147.0% during the 3rd quarter. SBI Securities Co. Ltd. now owns 10,253 shares of the biopharmaceutical company's stock worth $56,000 after purchasing an additional 6,102 shares in the last quarter. Swiss Life Asset Management Ltd purchased a new stake in shares of Ardelyx in the third quarter worth approximately $57,000. Finally, Sumitomo Mitsui Trust Group Inc. bought a new position in shares of Ardelyx in the fourth quarter valued at approximately $60,000. 58.92% of the stock is currently owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>一些對沖基金最近對 ARDX 的持倉進行了調整。DCF Advisers LLC 在第二季度收購了 Ardelyx 的新股份，價值約 39,000 美元。First Horizon Corp 在第四季度將其在 Ardelyx 的持股增加了 120.4%。First Horizon Corp 目前持有 7,906 股生物製藥公司的股票，價值 46,000 美元，此前在上個季度購買了 4,319 股。SBI Securities Co. Ltd.在第三季度將其在 Ardelyx 的持股增加了 147.0%。SBI Securities Co. Ltd.目前持有 10,253 股生物製藥公司的股票，價值 56,000 美元，此前在上個季度購買了 6,102 股。瑞士人壽資產管理有限公司在第三季度收購了 Ardelyx 的新股份，價值約 57,000 美元。最後，住友三井信託集團在第四季度收購了 Ardelyx 的新股份，價值約 60,000 美元。目前 58.92% 的股票由機構投資者和對沖基金持有。</p>
</div><h2>Ardelyx Company Profile</h2>
<div class="lb-trans"><h2>Ardelyx 公司簡介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>Ardelyx, Inc NASDAQ: ARDX is a clinical‐stage biopharmaceutical company focused on discovering, developing and commercializing targeted small molecule drugs for cardio‐renal and gastrointestinal diseases. The company's lead marketed product, tenapanor (sold under the brand name XPHOZAH in the United States), is approved for the treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis. Ardelyx's proprietary approach targets epithelial transporters in the gastrointestinal tract, offering localized activity with limited systemic exposure.</p>
<div class="lb-trans"><p>Ardelyx, Inc.（納斯達克：ARDX）是一家臨牀階段的生物製藥公司，專注於發現、開發和商業化針對心腎和胃腸疾病的小分子靶向藥物。該公司的主要市場產品 tenapanor（在美國以品牌名 XPHOZAH 銷售）已獲批准用於治療接受透析的慢性腎病患者的高磷血癥。Ardelyx 的專有方法針對胃腸道中的上皮轉運蛋白，提供局部作用並限制全身暴露。</p>
</div><p>Beyond tenapanor, Ardelyx's development pipeline includes treatments designed to address other complications in kidney disease and related metabolic disorders.</p>
<div class="lb-trans"><p>除了 tenapanor，Ardelyx 的開發管道還包括旨在解決腎病及相關代謝紊亂的其他併發症的治療方案。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>特色文章</h2>
</div><ul>
<li>Five stocks we like better than Ardelyx</li>
</ul>
<div class="lb-trans"><ul>
<li>五隻我們更看好的股票，勝過 Ardelyx</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QVJEWA" alt="" original-src="https://www.marketbeat.com/scripts/InsiderTradesChart.ashx?Prefix=NASDAQ&amp;Symbol=ARDX"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Ardelyx Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 Ardelyx 嗎？</h2>
</div><p>Before you consider Ardelyx, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考慮 Ardelyx 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Ardelyx wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，以便在更廣泛的市場注意到之前購買……而 Ardelyx 並不在名單上。</p>
</div><p>While Ardelyx currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Ardelyx 目前在分析師中被評為適度買入，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Insider Selling: Ardelyx (NASDAQ:ARDX) CEO Sells 41,666 Shares of Stock

Market Beat

Ardelyx

內幕交易：Ardelyx（納斯達克代碼：ARDX）的首席執行官出售了 41,666 股股票